clinical trial · NCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 330
HealthyTulisokibart Form 1Tulisokibart Form 2
brief summary
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
started
Mar 5, 2026
primary completion
Sep 3, 2026
completion
Sep 3, 2026
last updated
Apr 8, 2026
official title
A Randomized, Open-label, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Tulisokibart Delivered by 2 Different Autoinjectors in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol